Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash from Operations (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Cash from Operations data on record, last reported at 9566000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 51.34% year-over-year to 9566000.0; the TTM value through Sep 2025 reached 32071000.0, down 44.95%, while the annual FY2024 figure was 25424000.0, 6.22% down from the prior year.
  • Cash from Operations reached 9566000.0 in Q3 2025 per CRVS's latest filing, down from 5777000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 5157000.0 in Q1 2024 and bottomed at 9566000.0 in Q3 2025.
  • Average Cash from Operations over 4 years is 6665866.67, with a median of 6321000.0 recorded in 2024.
  • The widest YoY moves for Cash from Operations: up 36.42% in 2024, down 63.83% in 2024.
  • A 4-year view of Cash from Operations shows it stood at 7547000.0 in 2022, then surged by 31.54% to 5167000.0 in 2023, then plummeted by 63.83% to 8465000.0 in 2024, then fell by 13.01% to 9566000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 9566000.0 in Q3 2025, 5777000.0 in Q2 2025, and 8263000.0 in Q1 2025.